- In January 2025, bluebird bio, Inc., a leading player in gene therapy, received FDA approval for its LentiGlobin gene therapy for sickle cell disease, expanding its gene therapy portfolio. This approval marks a significant milestone for the treatment of hematologic diseases and offers patients a potential one-time treatment solution. The therapy is designed to increase healthy hemoglobin production in patients with sickle cell disease, improving their quality of life and potentially reducing the need for lifelong transfusions
- In December 2024, Gilead Sciences, Inc. launched a new clinical trial for its Yescarta gene therapy to treat relapsed or refractory B-cell lymphoma. The trial will evaluate the long-term efficacy and safety of Yescarta when combined with new immune-modifying therapies. This expansion in its oncology portfolio signals the continued progress in the gene therapy landscape, aimed at improving the survival rates of cancer patients
- In October 2024, Novartis AG expanded its Kymriah gene therapy offering to treat adult patients with large B-cell lymphoma. The expanded indication is expected to help further drive growth in the gene therapy market by offering a more comprehensive solution for lymphomas and other blood cancers. Novartis continues to focus on strengthening its oncology pipeline, positioning gene therapy as a key therapeutic modality
